Lorlatinib, is currently the only a listing of the three generations of ALK - TKIs drugs, phase I clinical study has shown its good therapeutic effect. In 2018, Lorlatinib for treatment of ALK positive in NSCLC patients with lung cancer cohort study...

MET gene (chromosome 7 long arm, contains 21 exon) coding c - MET protein is hepatocyte growth factor (HGF) tyrosine kinase receptor, HGF and c - MET with activation of downstream signaling pathways, promote cell proliferation, growth, migration, and...